Susan brings a wealth of experience, gained over 20 years in the pharmaceutical, biotech and healthcare industries. She has extensive financial management expertise, gained from working with start up companies to global PLCs, covering both public and private financing, including venture capital financing and IPOs. Susan also has extensive experience of M&A activity, including acquisition and divestment.
Susan has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 CEO commented: ‘Lab21 is now well established with facilities in both the UK and US, a large international customer base, and an expanding portfolio of products and services. Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company. I would also like to thank Maddy Kennedy, our previous CFO, whose contributions to the business have had a huge impact in ensuring Lab21 is in a strong position for future growth.’
For further information: Lab21 Graham Mullis, CEO Susan Lowther, CFO t: +44 (0)1223 395461 e: graham.mullis@lab21.com e: susan.lowther@lab21.com
For media and investor enquiries:
College Hill Tony Stephenson/Gemma Howe/Nicole Yost t: +44 (0)20 7866 7864 m: +44 (0)7989 855113 e: lab21@collegehill.com
About Lab21
Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies.
The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 international countries and is focused on infectious diseases for the blood-banking market.
The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalised medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease. Lab21's clinical reference laboratory and corporate office is based in Cambridge and has additional UK sites in Newmarket, Bridportand Ipswich. It also has operations in South Carolina, USA. The Company's investors include Excalibur, Nexus Medical Partners, Medicis Capital, Rowan Dartington and Kreos Capital.
Website: www.lab21.com
